Since joining Sanofi in 2014, Brian has contributed to partnering and business development activities through a number of different roles. He started as a member of the Sunrise team, where his efforts focused on building and maintaining a portfolio of investments, including MyoKardia, Portal, Warp Drive Bio, DiCE and Thermalin. Brian joined the Sanofi Business Development team in 2017 as head of External Innovation, Rare Diseases, has assumed additional responsibilities over the past three years and has been in this current role since 2019. He and his team are responsible for working with senior leadership to define an overall portfolio strategy, with accountability for identifying and securing external opportunities that fill portfolio and business needs for each of the therapeutic areas and technology platforms.

Prior to joining Sanofi, Brian was Vice President of Research and Development at Satori Pharmaceuticals, where he was a member of the Executive Leadership team and led chemical sciences and drug metabolism. He also advised several venture capital and life science groups; his efforts contributed to a number of successful financing rounds, as well as advancing R&D portfolios through key milestones.

Brian started his professional career with Pfizer (1994-2008), rising to the level of Senior Director. During this tenure, his responsibilities included shaping R&D strategy across multiple platforms and therapeutic areas and delivering clinical candidates in psychiatry, neurology, infectious diseases and metabolic disorders. Brian and his teams have been involved in the discovery of more than twenty development candidates, including the launched products Draxxin™, Convenia™, Cerina™ and Slentrol™.

Brian earned his bachelor’s degree from Colgate University in 1989. Following a year as a Fulbright Fellow in Dortmund, Germany, he initiated his doctoral work at the Massachusetts Institute of Technology, receiving his doctorate in chemistry in 1994.